Hybrid Lipid Nanocapsules: A Robust Nanoplatform for the Co-delivery of Resiquimod and mRNA

Files
MOSS-THESIS-2025.pdf (2.9 MB)
Author(s)
Moss, Avery Elizabeth
Advisor(s)
Editor(s)
Associated Organization(s)
Organizational Unit
Organizational Unit
Series
Collections
Theses and Dissertations
Supplementary to:
Permanent Link
https://hdl.handle.net/1853/78660
Abstract
The ever-progressing field of cancer immunotherapy has sparked interest in development of unique drug platforms. This thesis explores the use of hybrid lipid nanocapsule as a co-delivery platform for mRNA and resiquimod, a toll-like receptor 7/8 agonist. The co-formulation aimed to synergistically combine antigen expression through mRNA transfection with the innate immune stimulation by resiquimod. The formulation of hLNCs with engineered presented optimal characteristics for targeting tumors as well as excellent encapsulation efficiency of resiquimod. This co-delivery of resiquimod with mRNA may enhance immune activation and accurate delivery to target solid-state tumors.
Sponsor
Date
2025-05-19
Extent
Resource Type
Text
Resource Subtype
Thesis
Rights Statement
Rights URI